ReviewAsia Pacific allergy2013
Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective.
Review in Asia Pacific allergy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 57 citations in OpenAlex.
- Clinical characteristics of patients under General Medicine with drug allergies occurring during hospitalisation at a tertiary hospital.Singapore medical journal · 2026Article
- Stevens-Johnson syndrome associated with pancytopenia: a case report.Annals of medicine and surgery (2012) · 2024Article
- Hydroxychloroquine-Induced Stevens-Johnson Syndrome in the Patient with Systemic Lupus Erythematosus: A Case Report in Kurdish Region - Iraq.Mediterranean journal of rheumatology · 2023Article
- Carbamazepine-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Treated Successfully with Oral Cyclosporin: Case report and literature review.Sultan Qaboos University medical journal · 2021Review
- Drug-related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2021Review
- Quality of Life of Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) and Stevens-Johnson Syndrome (SJS) and/or Toxic Epidermal Necrolysis (TEN) Patients.Patient preference and adherence · 2021Article
- Structure-activity relationships of fraxamoside as an unusual xanthine oxidase inhibitor.Journal of enzyme inhibition and medicinal chemistry · 2017Article
- Is universal HLA-B*15:02 screening a cost-effective option in an ethnically diverse population? A case study of Malaysia.The British journal of dermatology · 2017Article
- Ibuprofen induced Stevens-Johnson syndrome - toxic epidermal necrolysis in Nepal.Asia Pacific allergy · 2016Article
- Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis.Experimental and therapeutic medicine · 2015Article
- Lamotrigine-induced toxic epidermal necrolysis confirmed by in vitro granulysin and cytokine assays.Asia Pacific allergy · 2014Article
- Diclofenac-serratiopeptidase combination induced stevens - johnson syndrome - a rare case report with review of literature.Journal of clinical and diagnostic research : JCDR · 2014Article
- Management of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis: Looking Beyond Guidelines!Indian journal of dermatologyArticle
- Stevens-Johnson syndrome and toxic epidermal necrolysis: a cross-sectional analysis of patients in an integrated allergy repository of a large health care system.The journal of allergy and clinical immunology. In practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions (SCAR) to drugs which are associated with significant morbidity and mortality. High risk drugs in Asia are similar to those reported worldwide. Human leukocyte antigen (HLA)-related risk alleles for carbamazepine and allopurinol SCAR are unique to Asians. Although prognostic scoring systems like the SCORTEN have been used for more than a decade, pitfalls and caveats need to be recognized, in particular in patients with multiple medical co-morbidities and systemic features in SJS/TEN. In centres without a tertiary Burns Centre, SJS/TEN patients can still be managed successfully in general and dermatology wards with well-executed supportive/nursing care. Controversy remains regarding the effectiveness of immunomodulation in reducing SJS/TEN morbidity, mortality and hastening re-epithelialization. Despite paucity of robust evidence, intravenous immunoglobulins and ciclosporin remain the most commonly used modalities worldwide. Acute and long-term ocular effects are an important source of morbidity for which emerging ophthalmic therapies appear promising. Quality of life issues have now become an important outcome in patients with SJS/TEN as they often impact survivors' future attitudes towards pharmacotherapy. Even though pharmacogenetic testing for high-risk drugs appears to be the panacea for preventing carbamazepine- and allopurinol-induced SJS/TEN in ethnic Asians, many issues remain before health regulators in our region can conclusively determine whether testing should be made mandatory or highly recommended as standard of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.